Galderma Switzerland

Dr Nicolas Rachinel
Licensing Project Manager 
Dr Johannes Voegel
Head of External Early-Stage Opportunities 

Genericon Pharma Gesellschaft m.b.H. Austria

Mrs Albena Hubmann
Head of Business Development 

GeneriNobel GmbH Germany

GeneriNobel is a privately owned pharmaceutical company, based in Germany, which outlicenses generic drugs (Rx) and OTC developments for the European market.

Key therapeutic areas are cardiovascular diseases, central nervous system and metabolism. GeneriNobel has a focus on dossier development, registration and outlicensing of generic / OTC drugs and represents the marketing authorization / dossier portfolio of its partner, the turkish multinational pharmaceutical company Nobel Ilaç (own R&D and manufacturing of APIs and finished products).

We offer:

* Out-licensing of generic / OTC drugs (dossiers) at an advanced stage of regulatory approval procedure, e. g. Rosuvastatin.

* Out-licensing of generic / OTC drugs (marketing authorisations / dossiers) with granted marketing authorisations in Germany and which are available for further registration procedures in Europe, e. g. Solifenacin, Rasagiline, Duloxetine, Aripiprazole, Memantine, Irbesartan and Irbesartan-HCTZ, Sildenafil, Escitalopram, Pantoprazole and Omeprazole.

We are interested in:

Marketing and Sales companies who are interested to in-license products of our Portfolio.

We are NOT interested in:

* regulatory service providers, IP service providers, legal advisors, APIs.

Dr Wolfgang Bäurle
Managing Director 

George Health Medicines United Kingdom

George Health Enterprises is the commercial arm of The George Institute for Global Health. George Health Medicines (a wholly owned subsidiary of GHE)  is focussed on the late stage development and key territory registration of pharmaceutical products which have resulted from The George Institute's ground-breaking research into the treatment of non-communicable diseases. George Health Medicines is seeking appropriate commercial partners globally for the medicines which it developes. The short term pipeline includes innovative medicines for the prophylaxis of cardiovascular disease and for the primary treatment of hypertension and Type II diabetes.

Dr Karl Roberts
Dr Karl Roberts
Chief Business Officer 

GHO Capital United Kingdom

Dr Christian Fellowes
Vice President 

Glenmark Pharmaceuticals SA Switzerland

Dr Joseph O'Sullivan
VP and Head of Global BD&L for Innovative Products 

goetzpartners Corporate Finance GmbH Germany

Ulrich Kinzel
Managing Director 

Hayfa Konrad France

Consultant

Roche Diagnostics GmbH

Mrs Hayfa Konrad
Lawyer 

Helm AG Germany

Helm AG is a Hamburg- based, privately owned company and represented by own subsidiaries in more

than 30 countries worldwide.

In cooperation with highly acclaimed international partners, Helm offers developments of generic

pharmaceuticals, IP researches, registrations of high quality e-CTD dossiers, launch and life cycle

management.

Our global presence and extensive variety of excellent service functions mean that Helm is your ideal

partner for all stages of the product life cycle from the initial idea generation through to the launch and

supply of the medicinal product.

We offer:

-High quality e-CTD dossiers per current EU-requirements and international registration strategies.

-Tailor made portfolio ideas.

- Excellent project management

- Collaborations for innovative technology platforms.

We are interested in:

- Identifying out-licensing and co-operation opportunities - especially for EU, Nordics, UK, LATAM, MENA

& CIS markets.

- Exploring product & brand acquisition opportunities in the targeted territories.

- Divestment of companies

We are NOT interested in:

- Regulatory Services

- CRO + CMO Services

Kathrin Casula
Kathrin Casula
Senior Licensing Manager 
Clara Vitaller
Licensing Manager 

Helsinn Healthcare Switzerland

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. Since 2012, Helsinn has been coordinating clinical and regulatory activities in China from Beijing and in 2017 established an office in Shanghai to pursue commercial activities. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, and the U.S., as well as a product presence in approximately 190 countries globally.

Website:
www.helsinn.com
Mr Rachid Benhamza
Mr Rachid Benhamza
Director, Head Corporate Product Management